RT Journal Article
SR Electronic
T1 Cognitive Impairment and Noncommunicable Diseases in Egypt’s Aging Population: Insights and Implications from the pilot of the Longitudinal Study of Egyptian Healthy Aging “AL-SEHA”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.16.23297117
DO 10.1101/2023.10.16.23297117
A1 Moustafa, Sara A.
A1 Deif, Reem
A1 Gaballah, Nada
A1 Salama, Mohamed
YR 2023
UL http://medrxiv.org/content/early/2023/10/17/2023.10.16.23297117.abstract
AB As the global population ages, the prevalence of cognitive impairment among older individuals has been steadily rising. Egypt, like many countries, is grappling with the challenges posed by an aging demographic. Cognitive impairment not only affects the quality of life of older adults but also imposes significant burdens on healthcare systems and societies as a whole. This paper presents findings from the pilot phase of the Longitudinal Study of Egyptian Healthy Aging, known as “AL-SEHA,” shedding light on the intricate relationship between cognitive impairment and noncommunicable diseases (NCDs) in Egypt’s aging population.KEY MESSAGESThe increasing prevalence of cognitive impairment among the aging population creates a need for a comprehensive understanding of its implications on the individuals’ quality of lifeA significant association between cognitive impairment and non-communicable diseases exists and further research can help in the strategic allocation of resources for designing the most effective interventionsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe present work has been supported by the German Academic Exchange Services (DAAD), through the funding program: Higher Education Dialogue with the Muslim World, project (Ageing in the East Mediterranean Region: EMage). This work benefitted from an incentive grant from the World Health Organization (WHO) as part of the WHO Global Noncommunicable Disease (NCD) Platform Young Researchers Programme (Grant reg. № 2022/1256080).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by IRB of the American University in Cairo (IRB-AUC). The patients/participants provided their written informed consent to participate in this study. The current work has been approved by the IRB of the American University in Cairo. IRBAUC_ Case# 2021-2022-029I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are fully available and without restrictions